Moreover, correlations between high TMB and the ICB therapeutic benefit were observed in some cohorts, including non-small cell lung cancer treated with anti-PD-1/L1 therapy (Rizvi et al., 2015) and melanoma treated with CTLA4 inhibitors (Van Allen et al., 2015) et al. Our study confirmed that Piezo2 expression was negatively correlated with TMB in BRCA, BLCA, STAD, KIRP, and other 11 cancers. The gene discussed is PIEZO2; the disease is melanoma.